Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Hum Psychopharmacol ; 36(4): e2779, 2021 07.
Article in English | MEDLINE | ID: mdl-33559925

ABSTRACT

OBJECTIVE: Endocannabinoids have been implicated in the pathophysiology of Major Depressive Disorder (MDD) and might represent potential targets for therapeutic intervention. Objectives of the study were: (1) to measure plasma levels of endocannabinoids in a group of antidepressant-free depressed outpatients; (2) to explore their relationship with the severity of depressive symptoms as subjectively perceived by the patients; and (3) to investigate the effect of the selective serotonin reuptake inhibitor escitalopram on endocannabinoid levels. METHODS: We measured plasma levels of the two major endocannabinoids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anadamide), in 12 drug-free outpatients diagnosed with MDD and in 12 matched healthy controls. In the patient group, endocannabinoids plasma levels were assessed at baseline and after 2 months of treatment with escitalopram. RESULTS: Baseline plasma levels of the two endocannabinoids did not differ between depressed patients and healthy controls. However, there was a significant inverse correlation between 2-arachidonoylglycerol levels and the severity of subjectively perceived depressive symptoms. Treatment with escitalopram did not change endocannabinoid levels in depressed patients, although it caused the expected improvement of depressive symptoms. CONCLUSIONS: Our results suggest that 2-arachidonylglycerol, the most abundant endocannabinoid in the central nervous system, might act to mitigate depressive symptoms, and raise the interesting possibility that 2-arachidonylglycerol and anandamide are differentially regulated in patients affected by MDD. Also, our data suggest but do not prove that the endocannabinoid system is not regulated by serotonergic transmission, at least in depressed patients.


Subject(s)
Depressive Disorder, Major , Arachidonic Acids , Depression , Depressive Disorder, Major/drug therapy , Endocannabinoids , Escitalopram , Glycerides , Humans
2.
Neuropsychiatr Dis Treat ; 12: 737-43, 2016.
Article in English | MEDLINE | ID: mdl-27099504

ABSTRACT

INTRODUCTION: Although adjustment disorder (AD) is considered as residual diagnosis and receives little attention in research, it plays an important role in clinical practice and also assumes an increasingly important role in the field of legal medicine, where the majority of diagnostic frameworks (eg, mobbing) often refer to AD. Our study aimed to look for specific stressor differences among demographic and clinical variables in a naturalistic setting of patients with AD. METHODS: A restrospective statistical analysis of the data of patients diagnosed with AD from November 2009 to September 2012, identified via manual search from the archive of the outpatient setting at the University Unit of Psychiatry "A. Fiorini" Hospital, Terracina (Latina, Italy), was performed. RESULTS: The sample consisted of 93 patients (46 males and 47 females), aged between 26 and 85, with medium-high educational level who were mainly employed. In most cases (54.80%), a diagnosis of AD with mixed anxiety and depressed mood was made. In all, 72% of the sample reported a negative family history for psychiatric disorders. In 22.60%, a previous history of psychopathology, especially mood disorders (76.19%), was reported. The main stressors linked to the development of AD were represented by working problems (32.30%), family problems (23.70%), and/or somatic disease (22.60%) with significant differences with respect to age and sex. Half of the patients were subjected to a single first examination; 24.47% requested a copy of medical records. CONCLUSION: Confirming previous data from previous reports, our results suggest that AD may have a distinct profile in demographic and clinical terms. Increased scientific attention is hoped, particularly focused on addressing a better definition of diagnostic criteria, whose correctness and accuracy are critical, especially in situations with medicolegal implications.

3.
Riv Psichiatr ; 50(1): 43-6, 2015.
Article in Italian | MEDLINE | ID: mdl-25805355

ABSTRACT

Shared psychotic disorder (folie à deux) is a rare condition characterized by the transmission of delusional aspects from a patient (the "dominant partner") to another (the "submissive partner") linked to the first by a close relationship. We report the case of two Moroccan sisters who have experienced a combined delusional episode diagnosed as shared psychotic disorder. In these circumstances, assessment of symptoms from a cross-cultural perspective is a key factor for proper diagnostic evaluation.


Subject(s)
Shared Paranoid Disorder/diagnosis , Siblings/psychology , Adult , Antipsychotic Agents/therapeutic use , Cross-Cultural Comparison , Delusions/diagnosis , Female , Haloperidol/therapeutic use , Humans , Patient Compliance , Shared Paranoid Disorder/drug therapy
4.
Riv Psichiatr ; 48(5): 375-85, 2013.
Article in Italian | MEDLINE | ID: mdl-24326750

ABSTRACT

In the last years, numerous researches led to identify endocannabinoid system, a sophisticated short-range signaling system which is located both in Central Nervous System (CNS) and in whole organism. Because of its flexibility of expression, it plays a modulatory role in controlling the answers to stimuli which disturb homeostasis. On one hand it lets them occur whilst on the other it limits them in order to protect organism from consequences due to excessive reaction. In the CNS, endocannabinoid system is able to control the release of several neurotransmitters thanks to its retrograde signaling, modulating synaptic activity. Analysing this property during preclinical studies, it came out that the endocannabinoid system is involved in numerous physiologic processes, such as neuroendocrine axes, food consumption, brain reward and satisfaction mechanisms, memories storing and extinction, emotions and neurodevelopment regulation. Such discoveries have led researchers to suppose and investigate an alteration of this system in the physiopathology of some psychiatric disorders such as anxiety disorder, depression, eating disorders, addiction and schizophrenia. Results of such studies on animal models show a possible involvement of this system and were quickly followed by clinical studies which seem to confirm it. These findings might open new scenarios for understanding the pathogenesis of several psychiatric disorders and, at same time, they show new prospects for their treatment.


Subject(s)
Endocannabinoids/physiology , Mental Disorders/etiology , Anxiety/etiology , Depression/etiology , Humans , Hypothalamo-Hypophyseal System/physiology , Neuronal Plasticity/physiology , Pituitary-Adrenal System/physiology , Schizophrenia/etiology , Stress, Psychological/etiology
5.
Case Rep Psychiatry ; 2013: 926395, 2013.
Article in English | MEDLINE | ID: mdl-23762723

ABSTRACT

Several neurological side effects induced by tacrolimus are described in the scientific literature, ranging from mild neurological symptoms to delirium and psychosis. We report the case of a 46-year-old man with no prior psychiatric history who suddenly manifested manic-like psychosis associated with elevated trough tacrolimus blood concentrations 17 years after kidney transplant. The use of antipsychotics may improve the severity of symptoms; but in order to obtain a complete remission, the reduction in the dose of tacrolimus, or its replacement with alternative immunosuppressant therapies, is recommended.

SELECTION OF CITATIONS
SEARCH DETAIL
...